首页> JAMA surgery> Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jessica,Mok

第一单位： Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom.;Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom.;National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom.

作者： Jessica,Mok ^[1] ; Mariam O,Adeleke ^[2] ; Adrian,Brown ^[1] ; Cormac G,Magee ^[1] ; Chloe,Firman ^[1] ; Christwishes,Makahamadze ^[3] ; Friedrich C,Jassil ^[3] ; Parastou,Marvasti ^[4] ; Alisia,Carnemolla ^[5] ; Kalpana,Devalia ^[6] ; Naim,Fakih ^[7] ; Mohamed,Elkalaawy ^[7] ; Andrea,Pucci ^[7] ; Andrew,Jenkinson ^[7] ; Marco,Adamo ^[7] ; Rumana Z,Omar ^[2] ; Rachel L,Batterham ^[1] ; Janine,Makaronidis ^[1]

作者单位： Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom.;Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom.;National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom. ^[1] Department of Statistical Science, University College London, London, United Kingdom. ^[2] Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom.;Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom. ^[3] Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom.;National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom. ^[4] Division of Medicine, University College London Centre for Obesity Research, Rayne Institute, London, United Kingdom. ^[5] Bariatric Surgery Department Homerton University Hospital National Health Service Trust, London, United Kingdom. ^[6] Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals, National Health Service Foundation Trust, London, United Kingdom. ^[7]

医学主题词成年人(Adult);人类(Humans);女(雌)性(Female);中年人(Middle Aged);男(雄)性(Male);降血糖药(Hypoglycemic Agents);糖尿病, 2型(Diabetes Mellitus, Type 2);治疗结果(Treatment Outcome);体重减轻(Weight Loss);胰高血糖素样肽1(Glucagon-Like Peptide 1);减肥手术(Bariatric Surgery);双盲法(Double-Blind Method)

DOI 10.1001/jamasurg.2023.2930

PMID 37494014

发布时间 2025-01-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

JAMA surgery

2023年158卷10期

1003-1011页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

JAMA surgery

2023年158卷10期

1003-1011页

检索历史清除

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.

JAMA surgery

相似文献

同项目论文

JAMA surgery

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.

JAMA surgery

相似文献

同项目论文

JAMA surgery

相关期刊

检索历史清除